[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy-related\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy-related":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,122,0,25,[9,51,74,99,126,146,171,192,216,241,263,287,310,338,374,398,423,444,464,487,512,533,563,586,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100651176","prenatal-education-on-environmental-exposures-during-pregnancy-study-peeps-100651176",false,"NCT07758114","Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS)","PEEPS","Inclusion Criteria:\n\n* Must be at least 18 years old\n* Must be pregnant, trying, or a mom\n* Must not have any conditions that would prevent them from carrying out study activities\n* Must be able to complete surveys and understand instructions\n\nExclusion Criteria:\n\n* Participants will not be considered if they are younger than 18 and are not pregnant, trying, or a mom.",true,"FEMALE","18 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this project is to reduce maternal environmental exposures to toxicants through a patient education program designed to help pregnant women learn about exposure through consumption of contaminated seafood and to be able to use the lessons they learn to have a better understanding of risk.",[28,29,30,31,32],"Environmental Exposure","Pregnancy Related","Preterm Birth","Chronic Respiratory Disease","Neurodegenerative Diseases",[34,28,35,36,37],"Safe Seafood Consumption","Superfund","FDA Dietary Guide","Pregnancy","RECRUITING","2026-08-10",{"date":41,"type":42},"2026-08-12","ACTUAL",{"date":44,"type":22},"2026-08",{"date":46,"type":22},"2029-04",{"name":48,"class":49},"The University of Texas Medical Branch, Galveston","OTHER",2,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100651148","cesarean-delivery-outcomes-in-maternal-critical-care-100651148","NCT07759024","Cesarean Delivery Outcomes in Maternal Critical Care","Maternal and Fetal Prognosis of Cesarean Delivery in Critically Ill Patients","CESAREA","Inclusion Criteria:\n\n* Women aged ≥18 years.\n* Pregnancy ≥22 weeks of gestation.\n* Admission (or planned admission) to a critical care unit.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Objection to the use of medical data.\n* Patients under legal protection (guardianship or similar legal measures).",{"count":60,"type":22},200,"OBSERVATIONAL","Cesarean delivery in critically ill pregnant women, especially outside the operating room, is a rare but high-risk situation for both mother and fetus. These patients often suffer from severe conditions (hypertensive disorders, hemorrhage, respiratory failure, infection, or trauma) and may require emergency cesarean in the ICU, emergency department, or prehospital setting.\n\nThey frequently need advanced organ support and face higher rates of complications, prolonged ICU stay, and maternal mortality. Non-OR environments also create challenges in sterility, coordination, and management. Neonatal outcomes are often impaired by iatrogenic prematurity.\n\nCurrent evidence is limited. A large nationwide registry is needed to better describe outcomes and support future protocols and recommendations.",[64,29],"Delivery Complication","NOT_YET_RECRUITING",{"date":67,"type":42},"2026-08-11",{"date":69,"type":22},"2026-10-01",{"date":71,"type":22},"2027-12-31",{"name":73,"class":49},"Société Française d'Anesthésie et de Réanimation",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":17,"sex":18,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100362119","project-for-reproductive-equity-through-volunteers-and-entrepreneurship-networks-and-technology-100362119","NCT03995043","Project for Reproductive Equity Through Volunteers and Entrepreneurship, Networks and Technology","Project for Reproductive Equity Through Volunteers and Entrepreneurship, Networks and Technology: The PREVENT Project Protocol","PREVENT","Inclusion Criteria:\n\n* Women 15-19 years of age\n* Reside within the study area for the duration of the study\n* Have a personal mobile phone and be willing to provide the phone number to the researchers to receive the intervention messages\n* Report being SMS literate (ie. able to read text messages in English or Swahili)\n* Be able and willing to return for follow-up after 12 months\n* Be able and willing to give written informed consent for enrollment in the study\n\nExclusion Criteria:\n\n* Be pregnant or planning pregnancy within 12 months (assessed when obtaining consent using HCG (human chorionic gonadotropin) urine dipstick).\n* Participation in another study or intervention that may affect the outcome of this study\n* Already utilizing a long-term form of contraception such as intra-uterine device, or implantable or inject-able contraception\n* Having a non-medical condition detected through screening that hinders study participation such as developmental or cognitive delay","15 Years","19 Years",{"count":85,"type":22},198,[25],"The PREVENT Project is a multifaceted, adolescent friendly, culturally competent program aimed to address the issues surrounding unplanned pregnancies and lack of access and uptake of contraceptive services among adolescent girls. The intervention uses a mobile platform that provides educational SMS (Short Message Service) messaging, interactive voice response, and connects adolescent girls to community based AFSRH (Adolescent Friendly Sexual Reproductive Health) counselling services, as well as discreet contraceptive access points headed by female entrepreneurs. The program will be piloted for 12 months in various wards and villages in rural and urban Kilimanjaro, Tanzania.The acceptability and practicality of the intervention will be assessed using mixed methods. Questionnaires and focus groups will be conducted with the study participants, as well as the medical and non-medical volunteers at the start and end of the pilot. The study will be heavily supported by all-female non-medical social entrepreneurs and sexual reproductive health community mentors (volunteers), and, all-female medical reproductive health team. Recruitment will also take place in hair saloons (local hair braiding and styling establishments) and other female run business such as tailors and female clothing stores that have enlisted to become contraceptive access points in the study. There will be 2 intervention groups, control and case group. Both groups will receive educational SMS (text) messages on SRH (Sexual Reproductive Health) and access individually tailored educational resources through interactive voice response (IVR) services\u002Fsystem via PREVENT mobile platform. In addition to personal support to be able to contact with a SRH community peer mentor in the community for AFSRH counselling and support. The case group will then have access to contraception provided with detailed and discreet information on accessing PREVENT contraceptive access points in all communities included in the study.",[89,29,90],"Contraception","Reproductive Behavior",{"date":41,"type":42},{"date":93,"type":22},"2027-12",{"date":95,"type":22},"2029-06-01",{"name":97,"class":49},"Dr. Karen Yeates",1,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":107,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":98},"100647407","interprofessional-simulation-program-for-clinical-resilience-and-empathy-project-inspire-100647407","NCT07707115","Interprofessional Simulation Program for Clinical Resilience and Empathy: Project INSPIRE","Interprofessional Simulation Program for Clinical Resilience and Empathy (INSPIRE) for Healthcare Teams Caring for Birthing Individuals With Substance Use Disorder in Utah","INSPIRE","Inclusion Criteria:\n\n* Employed at the University of Utah Hospital\n* Directly interfaces with birthing individuals (as clinical or non-clinical team member, e.g., physician, nurse, emergency medical technician, social worker)\n* English speaking\n\nExclusion Criteria:\n\n* Unable to provide informed consent","ALL",{"count":21,"type":22},[25],"The goal of this clinical trial is to develop and evaluate INSPIRE, an intervention for healthcare teams to improve care for individuals with substance use disorder (SUD) during their peri-delivery care. The main question it aims to answer is whether healthcare provider stigmas and behaviors change after receiving the training. The study will be implemented at the University of Utah.",[112,113,29,114,115],"Substance Use Disorders","Simulation Training","Patient-centered Care","Bias, Implicit",[117,118],"substance use disorders","Care received in hospital during labor & delivery and post-partum","2026-08-05",{"date":39,"type":42},{"date":122,"type":42},"2026-08-01",{"date":71,"type":22},{"name":125,"class":49},"University of Utah",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":98},"100511659","predicting-and-preventing-adverse-maternal-and-child-outcomes-of-opioid-use-disorder-in-pregnancy-100511659","NCT05942313","Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy","Inclusion Criteria:\n\n* Pregnant women with OUD and their infant\n* Currently on BUP\u002FMETH for OUD\n* Enrolled in prenatal opioid maintenance program\n* Age \\>18 years\n* Singleton pregnancy\n* Planned delivery at UPMC's Magee Womans Hospital\n* Positive opioid urine screen results\n\nExclusion Criteria:\n\n* Serious maternal medical illness as deemed by the PI that would make it challenging to comply with study procedures\n* HIV or AIDS\n* Known major fetal congenital abnormalities",{"count":133,"type":22},100,"This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.",[136,29],"Opioid Use Disorder","2026-08-04",{"date":139,"type":42},"2026-08-06",{"date":141,"type":42},"2023-08-28",{"date":143,"type":22},"2026-12-01",{"name":145,"class":49},"Ilana Hull",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":61,"phases":4,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":98},"100635763","elafibranor-pregnancy-surveillance-program-a-study-to-evaluate-the-safety-of-elafibranor-during-pregnancy-100635763","NCT07556913","Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy","Elafibranor Pregnancy Surveillance Program: A Post Marketing, Long Term, Multi-Center, Noninterventional, and Descriptive Study to Characterize Pregnancy and Maternal Complications and to Describe Effects on the Developing Fetus, Neonate and Infant Among Individuals Exposed to Elafibranor During Pregnancy","Inclusion Criteria:\n\n* Maternal exposure to at least one dose of elafibranor, either: Within three weeks prior to conception (based on the estimated date of LMP) or At any time during pregnancy (from the estimated date of conception through pregnancy outcome).\n* Participants who were previously enrolled in this program during a past pregnancy and who meet inclusion criteria #1 for the subsequent pregnancy are eligible to enroll again.\n* Informed consent or IRB\u002FIEC-approved waiver of informed consent (not applicable if reported by Ipsen PV according to usual pharmacovigilance practices).\n\nExclusion Criteria:\n\n* Participant with mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.",{"count":154,"type":22},3,"33 Months","The study will include participants who were exposed to at least one dose of elafibranor either within the three weeks before conception or at any time during pregnancy (based on estimated last menstrual period \\[LMP\\]).\n\nInformation will be collected from participants, their healthcare providers, published studies, and safety databases. Reports of pregnancy linked to elafibranor from clinical trials, spontaneous reports, or literature will also be included, with steps taken to avoid duplicates.\n\nThe study begins once the first participant is enrolled and ends after the last mother and child data are collected. It is planned to run for about 10 years, with infant follow-up lasting up to 2 years, for a maximum total duration of 12 years and 9 months.\n\nThe program is strictly observational. All medical care, visit schedules, and treatment decisions remain with healthcare providers. Only routine medical record data will be collected, and no extra tests or procedures are required.\n\nParticipation is voluntary, and written informed consent will be obtained before enrollment.",[29],[159,160,37],"Rare disease","Primary Biliary Cholangitis","2026-07-31",{"date":163,"type":42},"2026-08-03",{"date":165,"type":42},"2026-07-29",{"date":167,"type":22},"2039-01-31",{"name":169,"class":170},"Ipsen","INDUSTRY",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":178,"targetDuration":180,"studyType":61,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":98},"100535982","odevixibat-pregnancy-and-lactation-surveillance-program-a-study-to-evaluate-the-safety-of-odevixibat-during-pregnancy-andor-lactation-100535982","NCT06258902","Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and\u002For Lactation","Odevixibat Pregnancy and Lactation Surveillance Program: A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Odevixibat During Pregnancy and\u002For Lactation","Inclusion Criteria:\n\n* Exposure to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and\u002For at any time during lactation (up to 12 months of infant age or weaning, whichever comes first).\n* Informed consent or IRB-\u002FEC-approved waiver of informed consent (not applicable if reported by Albireo PV according to usual pharmacovigilance practices)\n\nExclusion Criteria:\n\n* Refusal to provide informed consent, if required",{"count":179,"type":22},20,"10 Years","The participants of this study will be of any age who are exposed to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and\u002For at any time during lactation (up to 12 months of infant age or weaning, whichever comes first.\n\nThis study will collect data obtained via a variety of sources, including enrolled pregnant or lactating participants, the healthcare providers (HCP) involved in their care or the care of their infants, if applicable, and Albireo pharmacovigilance.\n\nStudy start date is either start of data collection or first patient enrolled whatever occurs earlier.\n\nThe surveillance program is strictly observational; the schedule of office visits and all treatment regimens are determined by HCPs. Only data that are routinely documented in patients' medical records as part of usual care will be collected.\n\nNo additional laboratory tests or HCP assessments will be required as part of this surveillance program.",[29],[159,184,37,185],"PFIC","Lactation",{"date":163,"type":42},{"date":188,"type":42},"2023-09-28",{"date":190,"type":22},"2032-05-31",{"name":169,"class":170},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":98},"100335950","patient-centered-simulation-for-labor-and-delivery-100335950","NCT03654079","Patient Centered Simulation For Labor and Delivery","Inclusion Criteria:\n\n* Nulliparous pregnant women\n* In third trimester\n\nExclusion Criteria:\n\n• Not planning on delivering with Wake Forest School of Medicine OB\u002FGYN","44 Years",{"count":200,"type":22},50,[25],"Patient satisfaction is an important outcome in the evaluation and development of healthcare services. Studies have identified tools that successfully measure women's childbirth experiences, and have shown that multidimensional measures of women's satisfaction in labor and delivery provides a richer and diverse perspective on women's experiences of intrapartum care. Childbirth experience can have significant effects, both positive and negative, on women's immediate and long term health outcomes. Patients with negative experiences surrounding childbirth have been shown to have significant fear surrounding the labor and delivery experience that negatively impact subsequent deliveries. Often fear is worsened by a lack of knowledge of what to expect during labor. Women enrolled in this study will simulate some of the potentially stressful experiences that commonly occur during labor to determine if doing so decreases a woman's fear and anxiety about labor and delivery.",[29],[205,37,206,207],"Simulation","Labor and Delivery","Childbirth","2026-07-30",{"date":161,"type":42},{"date":211,"type":22},"2027-01",{"date":213,"type":22},"2027-11",{"name":215,"class":49},"Wake Forest University Health Sciences",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":224,"targetDuration":226,"studyType":61,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":98},"100566402","commercial-or-open-source-closed-loop-impact-on-pregnancy-study-100566402","NCT06654713","Commercial or Open Source Closed Loop Impact on Pregnancy Study","Commercial or Open Source Closed Loop Impact on Pregnancy (COSCLIP) Study","COSCLIP","Inclusion criteria:\n\n* Pregnant\n* Diagnosis of type 1 diabetes (T1D) prior to pregnancy\n* Active use of automated insulin delivery (AID) system\n\nExclusion criteria:\n\n* Diagnosis of other forms of diabetes (gestational diabetes, type 2 diabetes, monogenic diabetes)",{"count":225,"type":22},1000,"1 Year","The goal of this observational study is to better understand what happens when pregnant people with type 1 diabetes (T1D) use automated insulin delivery (AID) systems. The main questions this study aims to answer are:\n\n* What are the maternal and neonatal outcomes with AID system use in pregnancy?\n* What are the glycemic outcomes with AID system use in pregnancy?\n* What are the behavioral and emotional outcomes with AID system use in pregnancy?\n\nResearchers will compare pregnant people who use commercial AID systems and pregnant people who use open source AID systems to see if outcomes are different with these different types of systems.\n\nParticipants will be asked to remotely share their AID system data with the research team; complete online surveys regarding behavioral and emotional health; and sign an authorization to release health information to allow the research team to access medical records.",[229,230,231,29],"Type 1 Diabetes","Pregnancy, High Risk","Insulin Dependent Diabetes","2026-07-24",{"date":234,"type":42},"2026-07-27",{"date":236,"type":42},"2025-03-13",{"date":238,"type":22},"2029-12-31",{"name":240,"class":49},"University of California, San Francisco",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":98},"100515606","building-trust-and-uniting-teams-through-doula-partnership---bundle-100515606","NCT05993689","Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE","BUNDLE","Inclusion Criteria:\n\n* Self-reported Black or African American\n* Pregnant with singleton gestation\n* Has an established OBGY at Froedtert \\& the Medical College of Wisconsin (F\\&MCW) Health System\n\nExclusion Criteria:\n\n* Planning to deliver outside of F\\&MCW Health System\n* Receiving support beyond routing prenatal care, such as group prenatal care or has their own doula\n* Inability or unwillingness to provide informed consent","65 Years",{"count":250,"type":22},412,[25],"The BUNDLE study is a prospective mixed-methods study focused on the early integration of community doula into prenatal care. The study will have three phases: Phase 1 is the qualitative phase of conducting focus groups with Black\u002FAfrican American (AA) birthing people and with medical and community healthcare providers to elicit feedback on how best to integrate community-based doulas and obstetricians into one united model of prenatal care to promote trust and improved maternal health outcomes. Phase 2 tests the effectiveness of the newly developed model on healthcare engagement, trust, and adverse maternal outcomes using randomized control trial of 412 Black\u002FAA pregnant participants. Phase 3 is dissemination of BUNDLE findings in scholarly and community-based forums, including with healthcare leaders and policy makers in Wisconsin, advocating for doula coverage and health system sustainability of the integrated model.",[29],"2026-07-16",{"date":256,"type":42},"2026-07-20",{"date":258,"type":42},"2025-01-02",{"date":260,"type":22},"2030-06-30",{"name":262,"class":49},"Medical College of Wisconsin",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":98},"100509066","sleep-disordered-breathing-endothelial-function-and-adverse-events-in-pregnancy-100509066","NCT05908591","Sleep Disordered Breathing, Endothelial Function, and Adverse Events in Pregnancy","SLEEP: Sleep Disordered Breathing, Endothelial Function, and Adverse Events in Pregnancy","SLEEP","Inclusion Criteria:\n\n* over 18 years of age\n* pregnant (20-24 weeks gestation at enrollment)\n\nExclusion Criteria:\n\n* worked shift work past 11pm in the previous month\n* previously diagnosed with a sleep disorder by a physician",{"count":272,"type":22},109,"This is a prospective longitudinal cohort study whereby pregnant individuals are asked to complete an 8-day testing protocol to measure their sleep and cardiovascular health at two timepoints during pregnancy.",[29,275],"Sleep-Disordered Breathing",[277],"Cardiovascular Health","2026-07-15",{"date":280,"type":42},"2026-07-17",{"date":282,"type":42},"2023-01-01",{"date":284,"type":22},"2027-04-18",{"name":286,"class":49},"University of Alberta",{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":17,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":50},"100487272","reducing-psychological-barriers-to-prep-persistence-among-pregnant-and-postpartum-women-in-cape-town-south-africa-100487272","NCT05624931","Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa","Inclusion Criteria:\n\n* For participants across all three aims are:\n\n  * Female sex\n  * Aged 15+\n  * Pregnant and presenting antenatal care at the Gugulethu MOU\n  * HIV-negative\n  * Recent PrEP initiation (\\\u003C1 month ago) or PrEP adherence challenges, either documented (\\>2 weeks late to pick up PrEP refill) or self-reported\n  * Moderate to severe symptoms of posttraumatic stress and\u002For depression (defined as a score of ≥31 on PTSD Checklist for DSM-5 (PCL-5) and\u002For a score of ≥13 on the Edinburgh Postnatal Depression Scale (EPDS). Cutoff scores may be adjusted by 3-5 points to facilitate recruitment.\n\nExclusion Criteria:\n\n* There are no exclusion criteria with respect to parity or gravidity.\n\n  * Participants who are unable to provide informed consent or assent in English or Xhosa\n  * Have a significant psychiatric illness (e.g., active psychotic disorder or untreated bipolar disorder) that could interfere with participation will be excluded. Positive symptoms of active psychosis or mania will be assessed by the research assistants. They will be trained to identify delusions, hallucinations, disorganized or pressured speech, flight of ideas, and grandiosity as they speak to potential participants.\n  * Potential participants will also be asked if they have any health conditions that make it difficult for them to travel to the clinic.",{"count":294,"type":22},118,[25],"Pregnant women in South Africa (SA) are at high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) use during pregnancy is both safe and effective in preventing HIV. However, posttraumatic stress (associated with intimate partner violence and\u002For other traumas) and depression negatively impact PrEP adherence among women in SA. Addressing posttraumatic stress and depression will likely improve PrEP adherence and persistence (i.e., sustained PrEP adherence over time) during pregnancy and breastfeeding, which are periods of dramatically increased HIV risk. The overarching goal of this proposal is to develop and test the feasibility and acceptability of a cognitive behavioral intervention that targets common underlying factors of posttraumatic stress and depression to improve PrEP adherence and persistence during pregnancy and the postpartum transition. The specific aims of the project are to (1) explore the mechanisms by which posttraumatic stress and depression impact PrEP adherence and persistence during pregnancy via qualitative interviews; (2) develop a brief PrEP adherence and persistence intervention (\\~4 sessions) that reduces the negative impact of psychological mechanisms common to posttraumatic stress and depression on PrEP use, and builds behavioral skills to improve self-care; and (3) evaluate the feasibility, acceptability, and signals of preliminary efficacy of the intervention, which will be integrated into antenatal care, in a pilot randomized controlled trial. All data will be collected in the Midwife Obstetrics Unit (MOU) in Gugulethu, a peri-urban settlement and former township community outside of Cape Town, SA.",[298,299,29,300],"Depression","Posttraumatic Stress Disorder","Medication Adherence",[302],"HIV, pregnancy, PrEP",{"date":280,"type":42},{"date":305,"type":42},"2025-04-17",{"date":307,"type":22},"2027-07-30",{"name":309,"class":49},"Boston University Charles River Campus",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":98},"100522230","phase-3-multiple-micronutrient-supplementation-for-maternal-anemia-prevention-in-tanzania-100522230","NCT06079918","Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania","Individually Randomized Trial of Higher-dose Iron (60 mg, 45 mg) Compared to Low-dose Iron (30 mg) in Multiple Micronutrient Supplements in Pregnancy on Moderate and Severe Maternal Anemia","MMS-MAP","Inclusion Criteria:\n\n* Attending first ANC visit at study clinics\n* Pregnant women \\\u003C 20 weeks gestation by last menstrual period (LMP)\n* Aged ≥ 18 years old\n* Intending to stay in Dar es Salaam until 6 weeks post delivery\n* Provides informed consent\n\nExclusion Criteria:\n\n* Severe anemia (defined as hemoglobin \\\u003C 8.5 g\u002FdL per Tanzania standard of care)\n* Sickle cell disease (SS and SC) and hemoglobin C disease (CC) as tested by HemoTypeSC\n* Concurrently enrolled in another nutritional clinical trial\n* Pregnant women with disability or condition which would impair their ability to provide informed consent and complete study procedures.",{"count":319,"type":22},6381,[321],"PHASE3","This is an individually randomized controlled trial to assess the effect of multiple micronutrient supplements (MMS) containing 60 and 45 mg iron as compared to MMS containing 30 mg of iron (standard UNIMMAP formulation) on maternal moderate or severe anemia. This study will help inform countries like Tanzania that currently use IFA containing 60 mg of iron regarding the dose of iron to use in MMS.",[29],[37,325,326,327,328],"Multiple Micronutrient Supplementation","Iron","Anemia","Tanzania","2026-07-13",{"date":331,"type":42},"2026-07-14",{"date":333,"type":42},"2025-03-03",{"date":335,"type":22},"2027-06",{"name":337,"class":49},"George Washington University",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":363,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":50},"100457248","better-lifestyle-counseling-for-african-american-women-during-pregnancy-100457248","NCT05234125","Better Lifestyle Counseling for African American Women During Pregnancy","A Randomized Control Trial to Improve Metabolic Outcomes in African American Pregnant Women","BETTER","Inclusion Criteria:\n\n* African American pregnant woman.\n* Women between 16 and 22 GWs.\n* Overweight or obese - pregravid Body Mass Index \\>25.0 kg\u002Fm2.\n* Singleton gestation.\n* Established prenatal care at The University of Illinois Hospital \\& Health Sciences.\n* System Obstetric (UIHHSS' OB) clinics. Able to understand, speak and write in English.\n\nExclusion Criteria:\n\n* Multiple gestations.\n* Night-shift work.\n* Diagnosed sleep disorders.\n* Known fetal chromosomal or anatomical abnormalities.\n* Diagnosed mood disorders.\n* Gestational diabetes in early pregnancy.\n* Glycated Hemoglobin (HbA1c) ≥ 6.5%.\n* Hypoglycemic medications.\n* Stimulant medication or taking a sleeping aid.\n* Active drug abuse\u002Fexcessive alcohol intake.","40 Years",{"count":348,"type":22},150,[25],"The purpose of this randomized controlled trial is to establish the effectiveness of a culturally targeted and individually tailored behavioral intervention to promote maternal glucose metabolism in African American women.",[352,29,353,354,355,356,357,358,359,360,361,362],"Overweight or Obesity","Sleep Disturbances","Sleep Hygiene","Pregnancy Complications","Diversity","Stress, Psychological","Fitness Trackers","Exercise","African Americans","Disparities in Pregnancy Complications","Sleep Disparities",[364],"Sleep, Pregnancy, Intervention, glucose metabolism,","2026-07-07",{"date":367,"type":42},"2026-07-09",{"date":369,"type":42},"2022-08-16",{"date":371,"type":22},"2027-12-30",{"name":373,"class":49},"University of Illinois at Chicago",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":381,"maxAge":248,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":98},"100537934","telehealth-diaphragmatic-vs-pelvic-exercise-in-postpartum-pregnancy-related-pelvic-girdle-pain-100537934","NCT06284278","Telehealth: Diaphragmatic vs. Pelvic Exercise in Postpartum Pregnancy-related Pelvic Girdle Pain","Comparison of Diaphragmatic Breathing Exercise and Pelvic Stabilization Exercise in Postpartum Women With Pregnancy-related Pelvic Girdle Pain: A Real-time Telehealth-based Intervention","Inclusion Criteria:\n\n* Age between 20-65 years\n* Postpartum ≥ 3 months\n* Pain located in sacroiliac joints (i.e., pain located between the posterior iliac crest and gluteal fold)\n* Pregnancy-related cause of pelvic pain that pain occurs during pregnancy or after delivery (i.e., not traumatic or degenerative cause)\n* At least 2 positive findings of 6 pain provocation tests for pelvic pain\n* Score of Active Straight Leg Rise (ASLR) test \\> 0\n\nExclusion Criteria:\n\n* being pregnant or actively trying to get pregnant\n* having known causes of pelvic girdle pain, such as fractures and rheumatism\n* having undergone lumbar, pelvic, gynecologic or obstetric surgery\n* having current neurological symptoms and signs in lower extremities such as lumbar radiculopathy and myelopathy\n* having cancer\n* having cardiovascular disease\n* being diagnosed as having a psychiatric disease\n* active infection or infectious disease in the pelvis or abdomen\n* having experience with structured and supervised core or trunk exercise training programs.","20 Years",{"count":383,"type":22},60,[25],"The goal of this interventional study is to compare investigate the short-term and long-term effects of 8-week real-time telehealth-based diaphragmatic breathing exercise and pelvic stabilization exercise on pain, disability, and quality of life in postpartum women with pregnancy-related pelvic girdle pain.",[387,29,388],"Postpartum","Pelvic Girdle Pain","2026-07-01",{"date":391,"type":42},"2026-07-06",{"date":393,"type":42},"2024-03-01",{"date":395,"type":22},"2026-09-30",{"name":397,"class":49},"YI-JU TSAI",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":346,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":98},"100512089","real-time-continuous-glucose-monitoring-system-in-t2dm-with-pregnacy-100512089","NCT05947916","Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy","Effect of Real Time Continuous Glucose Monitoring System on Management of Women With Type 2 Diabetes Mellitus During Pregnancy in a Multidisciplinary Comprehensive System","Inclusion Criteria:\n\n* A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy\n* Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \\> 5.3 mmol\u002FL, and or 1 hour postprandial glucose \\> 7.8 mmol\u002FL, and or 2 hours postprandial glucose \\> 6.7 mmol\u002FL) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen.\n* Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery.\n* Voluntarily participate in the study, examine and follow up according to this project and sign informed consent.\n* Able to pass the screening period Adherence evaluation\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, specific type of diabetes or gestational diabetes\n* Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL\u002Fmin\u002F1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy.\n* Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications.\n* Patients who have received other interventional studies.",{"count":406,"type":22},240,[25],"The prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age is increasing rapidly, and low glucose compliance leads to an increased risk of adverse pregnancy outcomes for mothers and infants during pregnancy in women with T2DM. Real-time continuous glucose monitoring (CGM) is an important tool for glucose monitoring and patient education, as it can continuously record blood glucose throughout the day and provide real-time feedback on high and low blood glucose levels. This is a multicenter, open-label, randomized controlled clinical study to investigate the efficacy, safety, and maternal and infant pregnancy outcomes of using real-time CGM monitoring compared with conventional self-monitoring of blood glucose (SMBG) on the basis of multidisciplinary management in pregnant women with T2DM. One hundred and twenty pregnant women with T2DM in early pregnancy who were enrolled in intensive insulin therapy were randomly divided into the real-time CGM group and the conventional SMBG group. The real-time CGM intervention group wore real-time CGM for more than 50% of the pregnancy in addition to regular SMBG; the control group only performed regular SMBG. Both groups wore Medtronic iPro 2 for 3 days in early, mid and late pregnancy, and the time in the target range of blood glucose (TIR) was recorded in a blinded manner. Primary outcome: differences in TIR between the two groups of pregnant women in early, mid, and late pregnancy. Secondary outcomes included differences in glycated hemoglobin, hypoglycemia, insulin dose before delivery, pregnancy weight gain, and maternal and infant pregnancy outcomes.",[410,29,411,412,413],"Type2diabetes","Continuous Glucose Monitoring","Time in Range","Pregnancy Outcome","2026-06-30",{"date":416,"type":42},"2026-07-02",{"date":418,"type":42},"2024-01-30",{"date":420,"type":22},"2026-12-31",{"name":422,"class":49},"Peking University Third Hospital",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":98},"100646960","upper-vs-lower-extremity-bp-in-spinal-cesarean-using-clearsight-100646960","NCT07685730","Upper vs Lower Extremity BP in Spinal Cesarean Using ClearSight","Comparative Analysis of the Predictive Performance of Noninvasive Beat-by-Beat Blood Pressure and Flow Measurements at the Lower Extremity Versus the Upper Extremity for Neonatal Outcomes Under Spinal Anesthesia for Elective Cesarean Delivery","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Singleton pregnancy\n* Gestational age ≥ 37 weeks\n* Women undergoing CD under SAB or Combined Spinal-Epidural (CSE) electively.\n* Ability to consent in English and in Spanish language\n\nExclusion Criteria:\n\n* CD under or converted to general anesthesia\n* CD under epidural anesthesia or converted to epidural anesthesia\n* Diabetes Mellitus (DM)\u002FGestational Diabetes Mellitus (GDM)\n* Evidence of unstable cardiac disease other than HDP (including chronic hypertension, gestational hypertension, preeclampsia-eclampsia, and chronic hypertension with superimposed preeclampsia) judged by the investigator to have any impact on BP will make the subject unsuitable for participation in the study\n* Documented fetal anomaly\u002F congenital malformations and genetic syndromes\n* Intrauterine growth retardation\n* Unable to consent in English\u002FSpanish.\n* Prisoners",{"count":431,"type":22},327,"This is a single-center, prospective observational study in patients undergoing cesarean delivery under spinal or combined spinal-epidural anesthesia. It compares whether continuous noninvasive hemodynamic measurements from the lower extremity (toe) better predict neonatal outcomes than upper extremity (arm\u002Ffinger) measurements during spinal-induced hypotension.\n\nParticipants receive standard spinal anesthesia and routine blood pressure management, with additional monitoring using the ClearSight™ system at both upper and lower extremities from before spinal anesthesia through delivery.\n\nThe primary outcome is a composite of neonatal outcomes (APGAR scores, need for respiratory support, cord gases, and NICU admission). Secondary outcomes include maternal side effects and comfort.\n\nOverall, the study evaluates whether lower-extremity hemodynamic monitoring improves detection of clinically relevant hypotension and prediction of neonatal outcomes compared to traditional arm measurements.",[434,29,435],"Anesthesia","Blockades Neuromuscular","2026-06-29",{"date":391,"type":42},{"date":439,"type":42},"2025-02-06",{"date":441,"type":22},"2029-08-06",{"name":443,"class":49},"Ohio State University",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":17,"sex":107,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":98},"100484453","trial-of-community-based-patient-navigation-100484453","NCT05588245","Trial of Community-based Patient Navigation","A Pragmatic Trial of Integrating Community-based Patient Navigation Into the Continuum of Maternal Care for Black Women in a Safety-Net Health System: Effects on Maternal Health, Health Care, Morbidity, and Mortality","Inclusion Criteria:\n\n* A pregnant woman or individual (inclusive of all gender identities) who is Black and English-speaking (by self-report),\n* ≥18 years of age who is capable of consenting for oneself and who presents for prenatal care with a singleton pregnancy ≤ 20 weeks gestation (confirmed by medical record),\n* covered by Medicaid\n* for whom the AHC-Health Related Social Needs Tool (administered as part of standard clinical care for prenatal patients) identifies ≥1 unmet social needs\n* expectation to receive prenatal care and deliver at Grady and be available through 12-months postpartum to assure opportunity for exposure to the intervention, process, and outcome measure ascertainment.\n\nExclusion Criteria:\n\n* The intent to transfer care to a health system outside of metro Atlanta\n* incarceration, which would interfere with intervention provision and outcome ascertainment\n* adults unable to give consent\n* individuals who are not yet adults\n* prisoners\n* cognitively impaired individuals with impaired decision-making capacity\n* individuals who are not able to clearly understand and speak English (as the PPP-PN intervention is only available in English at this time)",{"count":452,"type":22},540,[25],"This study will test the effectiveness of a community-based patient navigator intervention from mid-pregnancy through 12 month postpartum for a high-risk population of medically underserved women. The RCT will enroll 540 pregnant women before 20 weeks of pregnancy and randomly allocate them into two different study arms from the time of prenatal enrollment through 12 months postpartum. If found to be effective, the community-based patient navigator intervention can be implemented as a standard of care at Grady and other provider practices serving high-risk women to improve maternal health outcomes and reduce racial disparities.",[29],"2026-06-19",{"date":458,"type":42},"2026-06-23",{"date":460,"type":42},"2024-01-25",{"date":335,"type":22},{"name":463,"class":49},"Emory University",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":98},"100636043","impact-of-lactation-antenatal-teaching-by-clinicians-and-healthcare-providers-100636043","NCT07560553","Impact of Lactation Antenatal Teaching by Clinicians and Healthcare Providers","Impact of Lactation Antenatal Teaching by Clinicians and Healthcare Providers: Randomized Control Trial","iLATCH","Inclusion Criteria:\n\n* Nulliparous mothers\n* Multiparous mothers who did not breastfeed previous children or breastfed previous children for less than 6 months\n\nExclusion Criteria:\n\n* Mothers planning to use formula\n* Multiparous mothers who previously breastfed for more than 6 months\n* Mothers with HIV\n* Mothers with a history of breast reduction surgery\n* Infants with major birth defects that may impede growth or feeding, such as cleft lip and\u002For palate, cardiac defects, and gastrointestinal defects","45 Years",{"count":474,"type":22},196,[25],"The purpose of this study is to increase the rate of exclusive breastfeeding at 6 weeks postpartum in the Inland Empire by addressing inadequate antenatal breastfeeding education for patients.",[29,478],"Breast Feeding, Exclusive","2026-06-18",{"date":458,"type":42},{"date":482,"type":42},"2026-06-16",{"date":484,"type":22},"2028-06",{"name":486,"class":49},"Loma Linda University",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":17,"sex":107,"minAge":4,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":500,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":98},"100394876","effects-of-systematic-cervical-exam-training-on-labor-and-delivery-care-100394876","NCT04421768","Effects of Systematic Cervical Exam Training on Labor and Delivery Care","Inclusion Criteria:\n\nHealthcare providers:\n\n• physicians, midwives, and labor and delivery nurses working on the Labor and Delivery unit within the Wake Forest Baptist Birth Center\n\nPatients:\n\n• any pregnant women receiving care on the Labor and Delivery unit of Wake Forest Baptist Birth Center\n\nExclusion Criteria:\n\nHealthcare providers:\n\n• none\n\nPatients:\n\n* placenta previa\n* vasa previa\n* any other contraindication to cervical exam",{"count":494,"type":22},1125,[25],"All physicians, nurses, and nurse midwives working on Labor and Delivery will be required to complete cervical exam simulation training. Data before and after institution of the training will be compared to determine if the training leads to less cervical exams during labor and increases consistency between examiners",[498,499,29],"Delivery Problem","Cervix; Pregnancy",[501,502,503],"vaginal delivery","labor cervical exam","labor and delivery","2026-06-15",{"date":506,"type":42},"2026-06-17",{"date":508,"type":42},"2020-07-23",{"date":510,"type":22},"2026-12",{"name":215,"class":49},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":519,"targetDuration":521,"studyType":61,"phases":4,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":98},"100480440","wakix-pitolisant-pregnancy-registry-100480440","NCT05536011","WAKIX® (Pitolisant) Pregnancy Registry","WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring","Inclusion Criteria:\n\n* Pregnant woman of any age\n* Consent to participate\n* Authorization for her HCP(s) to provide data to the registry\n* For participants with a diagnosis of narcolepsy: exposure to at least one dose of pitolisant or one dose of a comparator product, or, unexposed to pitolisant or comparator products at any time during pregnancy (i.e., any pregnant woman with a diagnosis of narcolepsy)\n* For participants without a diagnosis of narcolepsy: exposure to at least one dose of pitolisant or one dose of a comparator product at any time during pregnancy\n\nExclusion Criterion:\n\n• Occurrence of pregnancy outcome prior to first contact with the Registry Coordination Center (RCC) (i.e., retrospectively enrolled)",{"count":520,"type":22},1329,"21 Months","The WAKIX (pitolisant) Pregnancy Registry is a US-based, prospective, observational cohort study designed to evaluate the association between pitolisant exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.",[29,524],"Narcolepsy","2026-06-10",{"date":527,"type":42},"2026-06-12",{"date":529,"type":42},"2021-08-24",{"date":260,"type":22},{"name":532,"class":170},"Harmony Biosciences Management, Inc.",{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":17,"sex":107,"minAge":19,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":23,"phases":542,"briefSummary":543,"conditions":544,"keywords":548,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":98},"100569106","community-based-implementation-of-adapted-stac-100569106","NCT06689930","Community-based Implementation of Adapted STAC","Dissemination and Implementation of a Community-driven Approach to Improve the Health of Women, Infants, and Families: Pre-implementation Phase to Adapt Staying Healthy After Childbirth (STAC)","Inclusion Criteria (Interviews and Focus Groups):\n\n* Belong to the STAC-CAB or Lived Experience Group\n* Aged 18 or older\n\nInclusion Criteria (CBO Staff):\n\n* Staff of CBO participating in PDSA cycle\n* Aged 18 years or older\n\nInclusion Criteria (PDSA-Cycles):\n\n* Pregnant persons greater than or equal to 24 weeks gestation and prior to delivery or postpartum\n* Self-Identify as African American or Black\n* Aged 18 years or older\n* Capable of providing informed consent in English\n* Can follow M•care System use instructions in English\n* Have ownership of a functioning and reliable smartphone to upload and use the M•other App\n* Interested in preventing or managing blood pressure during pregnancy\n\nExclusion Criteria (PDSA-Cycles):\n\n* Persistent second or third trimester bleeding at time of enrollment\n* Premature rupture of membranes in the current pregnancy at time of enrollment\n* Known unrepaired maternal congenital heart disease requiring surgical correction\n* Maternal heart failure\n* Chronic kidney disease specifically requiring dialysis\n* On greater than two antihypertensive medications at time of enrollment",{"count":541,"type":22},46,[25],"This study is being done to adapt the Staying Healthy After Childbirth (STAC) intervention for implementation among Black Women and Birthing Persons (WBP).",[545,546,29,547],"Blood Pressure","Hypertension","Health Equity",[549,550,551,552,545,553],"Prenatal","Post Partum","Hypertensive Disorders of Pregnancy","Remote Patient Monitoring","Community-Based Participation","2026-06-09",{"date":556,"type":42},"2026-06-11",{"date":558,"type":42},"2025-05-22",{"date":560,"type":22},"2026-09",{"name":562,"class":49},"University of Wisconsin, Madison",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":4},"100521458","phase-3-multiple-micronutrient-supplementation-mms-vs-ifa-acceptability-crossover-trial-100521458","NCT06069856","Multiple Micronutrient Supplementation (MMS) vs IFA Acceptability Crossover Trial","Individually Randomized Crossover Trial of Multiple Micronutrient Supplementation (MMS) Versus IFA During Pregnancy in Tanzania","MIFA-ACT","Inclusion Criteria:\n\n* Attending first ANC visit at the study clinic\n* Pregnant women ≤ 15 weeks of gestation\n* Aged ≥ 18 years\n* Intending to stay in the study area for the duration of study\n* Provides informed consent\n\nExclusion Criteria:\n\n* Severe anemia (defined as Hb \\\u003C8.5 g\u002FdL per Tanzania standard of care)\n* Sickle cell disease (SS,SC, CC genotype) as tested by HemoTypeSC\n* Concurrent participation in other nutritional supplementation trial\n* Pregnant women with disability or condition which would impair their ability to provide informed consent and complete study procedures.",{"count":572,"type":22},130,[321],"This is an open-label individually randomized mixed methods cross-over trial to assess acceptability, preference, and side effects of IFA formulations with 60 mg of iron to MMS formulations with 60 mg of iron.",[29],[577,325,326,578,328],"Acceptability","IFA","2026-06-03",{"date":581,"type":42},"2026-06-04",{"date":583,"type":22},"2027-06-01",{"date":93,"type":22},{"name":337,"class":49},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":98},"100640006","care4mommies-in-action-a-compassion-based-intervention-100640006","NCT07611175","Care4mommies in Action: A Compassion-based Intervention","Care4mommies in Action: Promoting Maternal Psychological Adjustment in the Perinatal Period","Care4mommies","Inclusion Criteria:\n\n* being between 26 and 33 weeks into a single-fetus pregnancy,\n* being fluent in Portuguese\n\nExclusion Criteria:\n\n* currently receiving another psychological intervention","49 Years",{"count":596,"type":22},96,[25],"Becoming a mother is a life-changing event that many experience as a time of joy and affection. However, it can also be a period of great vulnerability and uncertainty with the potential to hinder the mother's well-being and bonding with the baby, and undermine the child's later emotional, social, and cognitive development. The mothers' emotional regulation skills, namely self-compassion, may be useful in protecting the mother and the mother-baby bonding, making them a valuable target of intervention during the perinatal period and a potential protective factor for mental health. Although compassion-based interventions (CBIs) have been proven effective in promoting well-being and reducing mental health difficulties across diverse populations, including the perinatal period, evidence of their impact on maternal well-being and the mother-baby bond remains limited. Thus, the research team propose to explore the acceptability, feasibility, and preliminary efficacy of a CBI during pregnancy on mothers' compassion abilities, and consequent impact on well-being and quality of mother-baby bonding at postpartum.\n\nThis pilot cluster randomised trial addresses the research question of 'Does the Care4mommies intervention work to promote mothers' compassion and higher quality of the mother-baby bonding?' Participants will be mothers enrolled in group birth preparation courses (i.e., TAU); those groups will be randomly allocated to Care4mommies plus TAU or TAU only and assessed at pre-intervention and post-intervention(prepartum), and 3-month follow-up(postpartum). At pre- and postintervention, participants will be asked to provide self-reported information on self-compassion, shame and guilt about caring, maternal-fetal attachment, fear of self-compassion, self-criticism, and mental health. At post-intervention, they will also be asked to appraise data collection procedures and the implementation feasibility of the Care4mommies; at follow-up, they will be asked to report on their bonding to their baby. Researchers expect that participants in the Care4mommies plus TAU condition will report significant gains at post-intervention and sustain them until follow-up, both in relation to the mother and in mother-baby bonding, compared to the TAU group. Also it is expected that changes in self-compassion-related variables will explain changes in mother-fetal attachment and postpartum mother-infant bonding.",[29],[601,602,603,604],"pregnancy","mother-baby bonding","Compassion focused intervention","self-compassion","2026-05-20",{"date":607,"type":42},"2026-05-28",{"date":609,"type":42},"2026-01-02",{"date":611,"type":22},"2026-12-08",{"name":613,"class":49},"Portucalense University",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":98},"100640412","maternal-intake-of-eggs-and-infant-neurodevelopment-100640412","NCT07583186","Maternal Intake of Eggs and Infant Neurodevelopment","MIND","Inclusion Criteria:\n\n* Pregnant females ≥18 years of age\n* 12 to 20-weeks' gestation at enrollment\n* No serious illnesses likely to confound study outcomes\n* Consuming 3 eggs\u002Fweek or less at enrollment and willing to increase consumption during the study\n* Singleton gestation\n* Available by telephone and text\n\nExclusion Criteria:\n\n* Less than 18 years at enrollment\n* Gestational age at enrollment \\\u003C12 or \\>20 weeks\n* Any serious illness likely to confound study outcomes\n* Consuming more than 3 eggs per week at enrollment\n* Unable\u002Funwilling to consume eggs until delivery or egg allergy\n* Expecting multiple infants\n* No access to telephone or text",{"count":133,"type":22},[25],"The fetal brain requires DHA, choline, lutein, and zeaxanthin (L\u002FZ) for development, dependent on maternal intake during pregnancy. However, many pregnant women do not meet daily requirements through diet or prenatal vitamins. Egg yolks are rich in choline, and women who consume eggs daily are more likely to meet the adequate intake of 450 mg\u002Fday. A recent study by Christifano et al. found that maternal egg and neuroprotective nutrient intake predicted neurodevelopment at 32 and 36 weeks of gestation. This study aims to determine if fetal neurodevelopment is enhanced among women who consume a prenatal diet emphasizing egg consumption (EGG) versus a healthy prenatal diet education control group (HPD). Women between 12-20 weeks' gestation will be randomized into EGG and HPD groups. The EGG group will receive education on the importance of prenatal choline and egg consumption and be encouraged to consume 10-14 eggs per week. The HPD group will receive education on a healthy prenatal diet. Both groups will be encouraged to take a DHA supplement, and dietary intake of choline, L\u002FZ, and DHA will be collected. Fetal heart rate variability will be measured at 36 weeks gestation and infant EEGs will be conducted postnatally to examine brain function. Increasing prenatal egg consumption is both economical and feasible to boost prenatal choline intake, promote offspring neurodevelopment, and guide prenatal dietary recommendations.",[29],[37,626,627],"Prenatal Nutrition","Neurodevelopment","2026-05-06",{"date":630,"type":42},"2026-05-13",{"date":632,"type":42},"2026-01-01",{"date":484,"type":22},{"name":635,"class":49},"University of Kansas Medical Center"]